DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) announced today the publication of positive findings from studies demonstrating the superior metabolic profile of VIAject™ ultra rapid-acting insulin compared to the rapid-acting analog, Humalog®, and regular human insulin in healthy volunteers and compared to regular human insulin in patients with type 1 diabetes. The articles appear in the current issues of the journals Diabetologia and Journal of Diabetes Science and Technology.
